Related Experiment Video
Updated: Jun 22, 2026
12:10
Retzius-Sparing Robot-Assisted Radical Prostatectomy
Published on: May 19, 2022
Prostate-sparing cystectomy: long-term oncological results.
Remco R de Vries1, Jakko A Nieuwenhuijzen, Harm van Tinteren
1Departments of Urology, the Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amstedam, the Netherlands.
BJU International
|June 25, 2009
Summary
Prostate-sparing cystectomy (PSC) offers oncologically safe outcomes comparable to standard cystoprostatectomy (SC). Careful patient selection is crucial for successful results in bladder cancer treatment.
Area of Science:
- Urology
- Oncology
- Surgical Oncology
Background:
- Bladder cancer treatment often involves radical cystectomy, which includes prostatectomy.
- Prostate-sparing cystectomy (PSC) is an alternative for select patients aiming to preserve prostate function.
Purpose of the Study:
- To evaluate the oncological outcomes of prostate-sparing cystectomy (PSC).
- To compare PSC outcomes with standard cystoprostatectomy (SC).
Main Methods:
- A cohort of 63 men underwent PSC between 1994 and 2006.
- Inclusion criteria: no bladder neck tumor or prostate cancer.
- PSC results were matched with standard cystoprostatectomy (SC) patients.
Main Results:
- 3- and 5-year disease-specific survival rates were 77% and 66% for PSC vs. 68% and 64% for SC.
- Local recurrence rates were 7.9% for PSC and 16% for SC.
- Subsequent prostate cancer detected in 3% of PSC patients, with no cancer-related deaths.
Conclusions:
- PSC demonstrates comparable oncological outcomes to SC.
- The procedure is considered oncologically safe for carefully selected patients.
- Further validation through broader clinical experience is recommended.
